research agreement
Fresenius and WuXi Biologics announce agreement to expand biosimilars pipeline
The agreement gives Fresenius exclusive option rights for up to 37 potential first-to-market biosimilar candidates
Sandoz announces collaboration agreement with Shanghai Henlius Biotech
The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company
Sandoz partners with Samsung Bioepis to develop up to five biosimilars
The agreement will expand the pipeline and builds on an existing partnership
EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy
An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019
FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma
The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis
EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases
The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease
EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases
The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications
Sandoz separates from Novartis as an independent spin-off company
The split allows Sandoz to strengthen its position in generics and biosimilars
Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US
Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease
Sandoz and Just-Evotec Biologics announce multi-year biosimilar partnership
The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates
Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities
The initiative wants to increase the global use of biosimilars by at least 30% by 2030
Biosimilars boosted by FDA’s landmark ruling for Boehringer’s Cyltezo
The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling